SmithKline Beecham’s cimetidine (Tagamet)
Executive Summary
Joint meeting of Gastrointestinal Drugs and OTC Drugs Advisory Committees will review H[2] antagonist for "use in episodic heartburn as an over-the-counter product" during Sept. 9 meeting at FDA's Parklawn Building, conference rooms D&E. On Sept. 10, Gastrointestinal Drugs committee will meet in closed session.